

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

(A)



(B)





FIG. 1

ATTACHMENTS OF LIGANDS THROUGH PRIMER REGION

(A)



(B)




FIG. 2

## ATTACHMENT OF LIGANDS BY INCORPORATION OF MODIFIED NUCLEOTIDE PRECURSORS




FIG. 3

Incorporation of Ligands through Modified Ribonucleotides




FIG. 4

Attachment of Ligands through a 3' tail




FIG. 5

Preparation of Gapped Circle

6/51




FIG. 6

Attachment of Ligands through hybridization to a 3' tail




FIG. 7

RNA with Ligands on Primer






FIG. 8

RNA with Ligands on Primer (Continued)




FIG. 9

RNA with Ligands on Multiple Primers

10/51




FIG. 10

RNA with Ligands on Multiple Primers (Continued)

11/51




FIG. 11

Single-stranded DNA with attached Ligands




FIG. 12

Single-stranded DNA with attached Ligands (continued)

13/51





FIG. 13

Linear Double-stranded DNA with attached Moieties on each strand




14/51



*FIG. 14*

Enhanced Delivery of Retroviral Vector  
to Haematopoietic Stem Cell




**FIG. 15**  
Enhanced Delivery of Vector  
DNA to Haematopoietic Stem Cell



16/51

(A) Dimeric Antibody formed from complete Antibody pieces



(B) Dimeric Antibody formed from F(ab') fragments





FIG. 16

Covalent Attachment of vector DNA to Dimeric Antibody



*FIG. 17*

Covalent attachment of Modified DNA  
to a Monovalent Antibody




FIG. 18

Modified DNA used as a Binder

19/51




FIG. 19

Synthetic Steps for Creation of Antibodies  
With Nucleic Acid Moieties Attached




FIG. 20  
 Continuation of Synthetic Steps






FIG. 21

Enhanced Binding of Antibodies to Antigens by Multimerization



*FIG. 22*

High Affinity Multi-Insulin Soluble Complex



**FIG. 23**

Multimerization of Insulin molecules by hybridization to discrete Sequences





24/51

Intron insertion site  
↓  
(A) -----TGCTCTCTAAGGGTCTACTC-----  
-----ACGAGAGATTCCCAGATGAG-----  
T7 RNA Polymerase Sequence

Splice Donor Site                      Splice Acceptor Site  
↓    ↓  
(B) -----CTCTAAGGTAAATAT - - - - - TGTATTTTAGATTCAA-----  
-----GAGATTCCATTTATA - - - - - ACATAAAATCTAAGTT-----  
SV40 Intron Sequence

(C) -----TGCTCTCTAAGGTAAATAT - - - - - TGTATTTTAGGGTCTACTC-----  
-----ACGAGAGATTCCATTTATA - - - - - ACATAAAATCCCAGATGAG-----

Insertion of SV40 Intron into polymerase coding sequence

Splice Donor Site                      Splice Acceptor Site  
↓    ↓  
(D) -----UGCUCUCUAAGGUAAAUAU - - - - - UGUUUUUUAGGGUCUACUC-----  
mRNA transcript containing intron

(E) -----UGCUCUCUAAGGGUCUACUC-----  
mRNA transcript after splicing has normal T7 Sequence


**FIG. 24**

Fusion of Intron into T7 RNA Polymerase Coding Sequence


25/51

(A)

Normal T7 RNA polymerase coding sequence




Synthesis of fragments by PCR Amplification of T7 or SV40 templates




(B)

Fusion of PCR fragments together in eucaryotic expression vector



(C)

Introduction of cassette with AS directed from T7 promoter




Active T7 RNA polymerase is only made in eucaryotic cells after splicing out of SV40 Intron

FIG. 25

Construction of T7 Expression Vector

(A)

Synthesis of pieces



(B)

Oligomers used for synthesis

- TSP-1    GGA ATT CGT CTC GAG CTC TGA TCA CCA CCA TGG ACA CGA TTA ACA TCG C
- TSP-2    GAC TAG TTG GTC TCG TCT CTT TTT TGG AGG AGT GTC GTT CTT AGC GAT GTT AAT C
- TSP 3    GGA ATT CGT CTC GGA GAA AGG TAA AAT TCT CTG ACA TCG AAC TGG C
- TSP-4    GAC TAG TGG TCT CCC CTT AGA GAG CAT GTC AGC
- TSP-5    GGA ATT CGG TCT CGG GTC TAC TCG GTG GCG AGG
- TSP-6    GAC TAG TCG TTA CGC GAA CGC AAA GTC
- INT-1    GGA ATT CGT CTC TAA GGT AAA TAT AAA ATT TTT AAG
- INT-2    GAC TAG TCG TCT CTG ACC CTA AAA TAC ACA AAC AAT TAG A

FIG. 26

Synthesis of Pieces for Construction of  
T7 RNA Polymerase with Intron

TSP1

Annealing of TSP1 with TSP2

5' GG AAT TCG TCT CGA GCT CTG ATC ACC ACC ATG GAC ACG ATT AAC ATC GC 3'

3' C TAA TTG TAG CGA TTC TTG CTG TGA GGA GGT TTT TTC TCT GCT CTG GTT GAT CAG 5'  
TSP2

Extension of TSP1/TSP2 by polymerase

5' GG AAT TCG TCT CGA GCT CTG ATC ACC ACC ATG GAC ACG ATT AAC ATC GCT AAG AAC GAC ACT CCT CCA AAA AAG AGA CGA GAC CAA CTA GTC 3'  
3' CC TTA AGC AGA GCT CGA GAC GTA TGG TGG TAC CTG TGC TAA TTG TAG CGA TTC TTG CTG TGA GGA GGT TTT TTC TCT GCT CTG GTT GAT CAG 5'

Bsa I

Digestion of TSP1/TSP2 product with Bsa I

5' GG AAT TCG TCT CGA GCT CTG ATC ACC ACC ATG GAC ACG ATT AAC ATC GCT AAG AAC GAC ACT CCT CCA AAA AA  
3' CC TTA AGC AGA GCT CGA GAC GTA TGG TGG TAC CTG TGC TAA TTG TAG CGA TTC TTG CTG TGA GGA GGT TTT TTC TCT

Digestion of PCR #1 clone (pL-1) with BsmB I

Bsm B1

5' GGA ATT CGT CTC G GAGA AAG GTA AAA TTC TCT GAC ATC GAA CTG GC-----  
CCT TAA GCA GAG CCTCT TTC CAT TTT AAG AGA CTG TAG CTT GAC CG-----

Ligation of Bsa I digested TS1/TS2 product to BsmB I digested PCR#1 clone

5' GG AAT TCG TCT CGA GCT CTG ATC ACC ACC ATG GAC ACG ATT AAC ATC GCT AAG AAC GAC ACT CCT CCA AAA AAG AGA AAG GTA AAA TTC  
3' CC TTA AGC AGA GCT CGA GAC GTA TGG TGG TAC CTG TGC TAA TTG TAG CGA TTC TTG CTG TGA GGA GGT TTT TTC TCT CAT TTT AAG  
TCT GAC ATC GAA CTG GC-----  
AGA CTG TAG CTT GAC CG-----

27/51

# FIG. 27

Formation of Nuclear Localisation Signal by Fusion of TSP1/TSP2 Product to  
Clone with PCR #1 product

Wild Type T7 nucleic and amino acid sequence

ATG	GAC	ACG	ATT	AAC	ATC	GCT	AAG	AAC	GAC	TTC	TCT	GAC	ATC	GAA	CTG	GC	-----
TAC	CTG	TGC	TAA	TTG	TAG	CGA	TTC	TTG	CTG	AAG	AGA	CTG	TAG	CTT	GAC	CG	-----
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16		

Modified T7 nucleic and amino acid sequence  
with Nuclear Localisation Signal (NLS) insertion

ATG	GAC	ACG	ATT	AAC	ATC	GCT	AAG	AAC	GAC	ACT	CCT	CCA	AAA	AAG	AGA	AAG	GTA	AAA	TTC	TCT	GAC	ATC	GAA	CTG	GC	-----
TAC	CTG	TGC	TAA	TTG	TAG	CGA	TTC	TTG	CTG	TGA	GGA	GGT	TTT	TTT	CTT	CTT	CTT	CTT	CTT	CTT	CTT	CTT	CTT	CTT	CTT	CTT
1	2	3	4	5	6	7	8	9	10																	

FIG. 28

Comparison of the 5' ends of the Nucleotide Sequences of Wild Type  
and Modified T7 RNA Polymerase

29/51




FIG. 29

Fusion of PCR Pieces to Construct  
T7 RNA Polymerase with an Intron

(A) Oligomers

HTA-1 GAT CAT TAG ACC AGA TCT GAG CCT GGG AGC TCT CTG GCT AAC TAG GGA ACC CAC TGC TTA AGC CTC AAG  
HTA-2 GAT CCT TGA GGC TTA AGC AGT GGG TTC CCT AGT TAG CCA GAG AGC TCC CAG GCT CAG ATC TGG TCT AAT

HTB-1 GAT CAC CTT AGG CTC TCC TAT GGC AGG AAG AAG CGG AGA CAG CGA CGA AGA CCT CCT CAA G  
HTB-2 GAT CCT TGA GGA GGT CTT CGT CGC TGT CTC CGC TTC TTC CTG CCA TAG GAG AGC CTA AGG T

HTC-1 GAT CAT AGT GAA TAG AGT TAG GCA GGG ATA CTC ACC ATT ATC GGT TCA GAC CCA CCT CCC AG  
HTC-2 GAT CCT GGG AGG TGG GTC TGA AAC GAT AAT GGT GAG TAT CCC TGC CTA ACT CTA TTC ACT AT

TER-1 AAT CTA GAG CTA ACA AAG CCC GAA AGG AAG  
TER-2 TTC TGC AGA TAT AGT TCC TCC TTT CAG C

(B) Cloning of AS and Terminator sequences into vector with T7 Promoter




FIG. 30

Insertion of Anti-Sense Sequences into  
T7 Directed Transcription Units

31/51




FIG. 31

Construct with t7 RNA polymerase and Anti-Sense directed from a T7 Promoter



32/51

A) Oligomers for introduction of T7 signals and polylinker

PL-1 TCG AGC CAT GGC TTA AGG ATC CGT ACG TCC GGA GCT AGC GGG CCC ATC GAT ACT  
AGT TAA ATG CAG ATC T

PL-2 CTA GAG ATC TGC ATT TAA CTA GTA TCG ATG GGC CCG CTA GCT CCG GAC GTA CGG  
ATC CTT AAG CCA TGG C




FIG. 32

Introduction of Poly-Linker for Creation of Protein Expression Vector

33/51




FIG. 33

Final steps for construction of Expression Vector




FIG. 34

Construct that produces single-stranded Anti-Sense DNA




FIG. 35

Continuation of Process from Figure 34




FIG. 36

Construct that produces RNA that is Reverse Transcribed to create  
Secondary DNA Constructs capable of directing transcription





FIG. 37

Construct which Propagates a Double Hairpin Production Center



In this Example, the sequence  $F' E' D'$  is a promoter, the sequence  $GHJK$  is an Anti-Sense sequence and  $X Y Z$  is a poly A signal

FIG. 38

Continuation of process from Figure 37




FIG. 39

Construct which propagates a Production Center capable of Inducible Suicide








FIG. 40

Use of tRNA primers to create a DNA construct  
for secondary production of transcripts


41/51



Normal U1



U1 with  
Bcl 1/Bsp EI  
piece removed



U1 with Anti-Sense  
sequence inserted

**FIG. 41**

Excision of sequences from U1 Transcript Region  
and Replacement with Novel Sequences

(A) Anti-sense oligomers

HVA-1 GAT CCG GAT TGA GGC TTA AGC AGT GGG TTC CCT AGT TAG CCA GAG AGC TCC CAG GCT CAG ATC TGG TCT AAT  
 HVA-2 CCG GAT TAG ACC AGA TCT GAG CCT GGG AGC TCT CTG GCT AAC TAG GGA ACC CAC TGC TTA AGC CTC AAT CCG  
 HVB-1 GAT CCG GAC CTT GAG GAG GTC TTC GTC GCT GTC TCC GCT TCT TCC TGC CAT AGG AGA GCC TAA GGT  
 HVB-2 CCG GAC CTT AGG CTC TCC TAT GGC AGG AAG AAG CGG AGA CAG CGA CGA AGA CCT CCT CAA GGT CCG  
 HVC-1 GAT CCG GAT GGG AGG TGG GTC TGA AAC GAT AAT GGT GAG TAT CCC TGC CTA ACT CTA TTC ACT AT  
 HVC-2 CCG GAT AGT GAA TAG AGT TAG GCA GGG ATA CTC ACC ATT ATC GTT TCA GAC CCA CCT CCC ATC CG  
 HVD-1 GAT CAG CAT GCC TGC AGG TCG ACT CTA GAC CCG GGT ACC GAG CTC GCC CTA TAG TGA GTC GTA TTA T  
 HVD-2 CCG GAT AAT ACG ACT CAC TAT AGG GCG AGC TCG GTA CCC GGG TCT AGA GTC GAC CTG CAG GCA TGC T

(B) Replacment of U1 sequences with HIV Anti-sense sequences





FIG. 42

Insertion of Anti-Sense Sequences into U1 Operons



**FIG. 43**

Predicted secondary structures for U1  
Transcripts with Anti-sense Substitutions




FIG. 44

Construction of U1 Multiple Operon Clone





FIG. 45

Construction of T7 Triple Operon


# pNDU1(A,B,C)

Triple U1 Operon Construct with HIV Anti-Sense



# TRI 101

Triple T7 Operon Construct with HIV Anti-Sense



## FIG. 46

Structures of Triple Operon Constructs  
from Figures 44 and 45





FIG. 47

Construction of Multiple T7 Operons in Vector coding for T7 RNA Polymerase





48/51



Global Statistics						
1. Green F1 3 JL_OCT05.023	Total = 7509					
2. Green Log F1 JL_OCT05.024	Total = 7509					
Hist	Region	Bounds	Counts	* Mean X	Mean Y	Mode xc
1.	LIN NEG	1 78	5714	76.1	63.65	78 14
	LIN POS	85 1002	1129	15.0	97.34	85 17
	OVERALL	1 1024	7509	100.0	70.28	70 23
2.	LOG NEG	2 2	4211	56.1	2.34	2 21
	LOG POS	2 1001	3407	45.4	4.76	3 69
	OVERALL	2 1001	7509	100.0	3.43	2 88

FIG. 48


Flow cytometry data measuring binding of anti -CD4+ antibody to HIV resistant U037 cells



49/51

*FIG. 49*

PCR amplification of gag region  
indicating absence of HIV in  
viral resistant cell line (2.10.16)  
after challenge



*FIG. 50*

Clone with target-lacZ fusion will have reduced expression of lacZ after transfection by HIV Anti-sense construct



51/51

Enzyme activity as expressed by  $A_{420}$  readings  
in extracts prepared from

(A)

	$2.5 \times 10^4$ cells	$5 \times 10^4$ cells	$1.0 \times 10^5$ cells
U 937 (untransfected)	0.018	0.023	0.034
U 937 (HIV A clone)	0.154	0.277	0.566
U937 (HIV A/Anti-A)	0.010	0.017	0.027
U 937 (HIV A/Anti-ABC)	0.013	0.021	0.035
U 937 (HIV A/Null DNA)	0.120	0.212	0.337

(B)

Expression of Beta-galactosidase activity by In situ assay:

U 937 (untransfected)	no blue spots in cells
U 937 (HIV A clone)	blue spots in cells
U 937 (HIV A/Anti A)	no blue spots in cells
U 937 (HIV A/Anti ABC)	no blue spots in cells
U 937 (HIV A/Null DNA)	blue spots in cells

FIG. 51

Expression of Beta-galactosidase activity  
in extracts